Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.

Abstract: Method for producing sodium bicarbonate particles by spray-drying of an aqueous solution comprising 1 to 10% by weight of sodium bicarbonate and an additive selected from the group consisting of: magnesium salt, sodium alkylbenzene sulfonate and soybean lecithin. Sodium bicarbonate particles obtainable by such process and comprising at least 20 mg of the additive per kg of sodium bicarbonate particles.

Abstract: Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.

Abstract: Goniochromatic/light reflecting cosmetic compositions well suited for making up the skin, lips, hair or integuments, contain (a) at least one goniochromatic coloring agent suited for creating a goniochromatic colored background and (b) an amount of light reflective particles suited for creating highlight points that are visible to the naked eye, formulated into (c) a topically applicable, physiologically acceptable medium therefor.

Abstract: The invention relates to the use of a compound of formula (I) or a salt thereof for combating animal pests, where the symbols and indices are defined in the specification.

Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.

Abstract: To provide a method which shows excellent effects in controlling pests in a field of soybean, corn or cotton. A method for controlling weeds in a field of soybean, corn or cotton, wherein the field of soybean, corn or cotton is treated with at least one PPO-inhibiting compound selected from the group consisting of flumioxazin, sulfentrazone, saflufenacil, oxyfluorfen, fomesafen-sodium, and the compound of the formula (I): before, at or after seeding with a seed of soybean, corn or cotton treated with one or more nematicides.

Abstract: The present invention relates to improved vitamin E formulations, as well as to the production of such formulations.

Abstract: The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Abstract: A pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from the group including Pinctadines, notably Pinctada maxima, margaritifera, and Tridacnes, notably Tridacnagigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopushippopus, Hippopusporcelanus, in pulverulent form, with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation; it also relates to the method of preparation thereof and to the uses thereof.

Abstract: This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided.

Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.

Abstract: A plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically beneficial substances to a plant, and for enhancing the translocation of such delivered substance(s) in or on the plant, the formulation comprising a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous carrier, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. The dispersion is preferably characterized in that at least 50% of the vesicles or microsponges are of a diametrical size of between 50 nm and 5 micrometer. The dispersion is further also characterized in that the micro-emulsion has a zeta potential of between ?25 mV and ?60 mV.

Abstract: The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.

Abstract: The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are thought to be suitable for use as herbicides. The invention therefore also relates to a method of controlling weeds, especially grassy monocotyledonous weeds, in crops of useful plants, comprising applying a compound of formula (I), or a herbicidal composition comprising such a compound, to the plants or to the locus thereof.

Abstract: The invention relates to a novel class of (S)-3?-substituted-abscisic acid derivatives and (±)-3?-substituted-abscisic acid derivatives, and methods of synthesizing the derivatives.

Abstract: The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: —pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained, —cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid, —continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the reaction mixture below 10 g/l, resulting in the crystallization of at least part of the sophorolactone present in the reaction mixture, —warming the reaction mixture to a temperature between 60° C. and 90° C.

Abstract: Herbicidal concentrate compositions containing glyphosate salts and tank mix compositions containing a combination of glyphosate salt and dicamba salt herbicides are described. A method of preparing a tank mix composition comprising a glyphosate component and a dicamba component is also described. The method includes combining a glyphosate concentrate composition, a dicamba composition comprising one or more salts of dicamba and dilution water to form the tank mix composition. The glyphosate concentrate composition comprises a glyphosate salt selected from the group consisting of the monoethanolamine salt, the potassium salt, and mixtures thereof at a glyphosate loading of at least about 240 grams acid equivalent per liter (g a.e./l), and the pH of a 5 wt. % acid equivalent dilution of the glyphosate concentrate composition is from about 5 to about 6.5.

Abstract: A strip of material for the delivery of an oral care active is disclosed. The strip of material includes a structural elastic-like film backing layer including a strainable network having a first region and a second region formed of substantially the same material composition, the first region providing a first, elastic-like resistive force to an applied axial elongation, and the second region providing a second distinctive resistive force to further applied axial elongation, thereby providing at least two stages of resistive forces in use; and an oral care composition disposed on the film, the oral care composition including an oral care active.